Patents by Inventor Jeremy Pratt

Jeremy Pratt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20160256449
    Abstract: The disclosure relates to the compound 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt thereof, intended for the treatment of Alzheimer's disease and other types of dementia.
    Type: Application
    Filed: March 8, 2016
    Publication date: September 8, 2016
    Inventors: Sophie CLAUDEL, Jeanne STEMMELIN, Pascal BARNEOUD, Philippe DELAY-GOYET, Mathilde LOPEZ-GRANCHA, Jeremy PRATT
  • 6-pyrimidinyl-pyrimid-4-one derivative
    Patent number: 8518939
    Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: August 27, 2013
    Assignees: Mitsubishi Tanabe Pharma Corporation, Sanofi
    Inventors: Kenji Fukunaga, Kazutoshi Watanabe, Pascal Barneoud, Jesus Benavides, Jeremy Pratt
  • 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE
    Publication number: 20120252812
    Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
    Type: Application
    Filed: May 9, 2012
    Publication date: October 4, 2012
    Applicants: SANOFI-AVENTIS, MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kenji FUKUNAGA, Kazutoshi WATANABE, Pascal BARNEOUD, Jesus BENAVIDES, Jeremy PRATT
  • 6-pyrimidinyl-pyrimid-4-one derivative
    Patent number: 8198437
    Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: June 12, 2012
    Assignees: Mitsubishi Tanabe Pharma Corporation, Sanofi-Aventis
    Inventors: Kenji Fukunaga, Kazutoshi Watanabe, Pascal Barneoud, Jesus Benavides, Jeremy Pratt
  • 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE
    Publication number: 20110021773
    Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
    Type: Application
    Filed: September 12, 2008
    Publication date: January 27, 2011
    Applicants: MITSUBISHI TANABE PHARMA CORPORATION, SANOFI-AVENTIS
    Inventors: Kenji Fukunaga, Kazutoshi Watanabe, Pascal Barneoud, Jesus Benavides, Jeremy Pratt
  • Use of low-molecular-weight heparins for the prevention and treatment of cerebral edemas
    Patent number: 6579858
    Abstract: Cerebral edema is prevented and treated by administering an effective amount of a low molecular weight heparin.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: June 17, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Véronique Mary, Jérémy Pratt, Jean-Marie Stutzman, André Uzan, Florence Wahl
  • Application of riluzole in the treatment of neurological lesions associated with trauma
    Patent number: 5830907
    Abstract: Application of riluzole or its pharmaceutically acceptable salts in the treatment of neurological lesions related to traumatic injuries, especially spinal, cranial or cranial-spinal injuries.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: November 3, 1998
    Assignee: Rhone-Poulenc Rorer, S.A.
    Inventors: Adam Doble, Erik Louvel, Jeremy Pratt, Jean-Marie Stutzmann
  • Application of riluzole for promoting restoration following radiation
    Patent number: 5656647
    Abstract: This invention relates to an application of riluzole or its pharmaceutically acceptable salts in the preparation of drugs having radiorestoring properties.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 12, 1997
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Jeremy Pratt, Jean-Marie Stutzmann